蒽环类药物相关心脏毒性的研究进展

Research progress of anthracycline-related cardiotoxicity

蒽环类药物是治疗恶性肿瘤最有效的化疗药物之一,临床广泛用于治疗血液系统恶性肿瘤和实体肿瘤。心脏毒性是蒽环类药物潜在的严重不良反应,也是限制其临床应用的重要考量因素。目前,蒽环类药物相关心脏毒性尚缺乏有效的治疗手段,早期监测和提前预防蒽环类药物相关心脏毒性的发生尤为重要。文章就蒽环类药物相关心血管疾病的发生机制、监测手段及防治策略进行综述,以期为临床防治蒽环类药物相关心脏毒性提供新思路。

Anthracyclines are one of the most effective chemotherapeutics for the treatment of malignant tumors,and are widely used clinically to treat hematological malignancies and solid tumors.Cardiotoxicity is a potentially serious adverse reaction of anthracyclines,and it is also an important factor limiting its clinical application.At present,there is no effective treatment for anthracycline-related cardiotoxicity.Early monitoring and prevention of anthracycline-related cardiotoxicity are particularly important.This article reviews the occurrence mechanism,monitoring methods and prevention and treatment strategies of anthracycline-related cardiovascular diseases,in order to provide new ideas for the clinical prevention and treatment of anthracycline-related cardiotoxicity.